SCHEMBL177389

SCHEMBL177389

CC(C)(C)[Si](C)(C)C#CCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168948 0.84
SCHEMBL17641593 0.80
SCHEMBL27605983 0.79
SCHEMBL336316 0.77
SCHEMBL16328954 0.77
SCHEMBL3354022 0.76
SCHEMBL8668976 0.76
SCHEMBL12085968 0.76
SCHEMBL30871009 0.76
SCHEMBL1504657 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478445-B2 Method for treating acute myeloid leukemia BIONOMICS LTD. (AU) 2022-10-25 US disclosed
US-20210177797-A1 METHOD FOR TREATING ACUTE MYELOID LEUKEMIA BIONOMICS LIMITED (AU) 2021-06-17 US disclosed
CN-107427487-B Combination treatment regimen 生态学有限公司 2021-02-26 CN disclosed
CN-111447972-A Method for treating acute myeloid leukemia 生态学有限公司 2020-07-24 CN disclosed
US-20200069729-A1 Combination Therapy for Treating Proliferative Diseases BIONOMICS, LTD (AU) 2020-03-05 US disclosed
US-10137105-B2 Combination treatment protocol BIONOMICS LIMITED (AU) 2018-11-27 US disclosed
EP-2854796-B1 COMBINATIONS OF A VASCULAR DISRUPTING AGENT AND A HYPOXIA-TARGETING AGENT FOR USE IN THE TREATMENT OF CANCER BIONOMICS LTD (AU) 2018-11-14 EP disclosed
US-20180289739-A1 Combination Therapy for Treating Proliferative Diseases BIONOMICS LTD (AU) 2018-10-11 US disclosed
US-9987293-B2 Method for treating chronic lymphocytic leukemia BIONOMICS LIMITED (AU) 2018-06-05 US disclosed
US-20180042887-A1 COMBINATION TREATMENT PROTOCOL BIONOMICS LIMITED (AU) 2018-02-15 US disclosed
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD (AU) 2011-12-29 US disclosed
EP-2344484-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF Akaal Pharma Pty Ltd (AU) 2011-07-20 EP disclosed
US-20110130367-A1 Combination Therapy for Treating Proliferative Diseases BIONOMICS LIMITED (AU) 2011-06-02 US disclosed
US-20100292190-A1 NOVEL TUBULIN POLYMERISATION INHIBITORS BIONOMICS LIMITED (AU) 2010-11-18 US disclosed
WO-2010043000-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF AKAAL PHARMA PTY LTD (AU) 2010-04-22 WO disclosed
US-20100004208-A1 SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS BIONOMICS LIMITED (AU) 2010-01-07 US disclosed
EP-1848704-A1 NOVEL TUBULIN POLYMERISATION INHIBITORS Bionomics Limited (AU) 2007-10-31 EP disclosed
WO-2006084338-A1 NOVEL TUBULIN POLYMERISATION INHIBITORS BIONOMICS LIMITED (AU) 2006-08-17 WO disclosed
US-5536732-A REDUCING INFECTIOUSNESS OF HIV MERRELL PHARMACEUTICALS INC. (US) 1996-07-16 US disclosed
US-5252587-A Viricides, aids therapy, antidiabetic agent MERRELL DOW PHARMACEUTICALS, INC. (US) 1993-10-12 US disclosed